Printer Friendly

TSI CORPORATION ACQUIRES GERMAN PRECLINICAL TESTING FACILITY

 TSI CORPORATION ACQUIRES GERMAN PRECLINICAL TESTING FACILITY
 WORCESTER, Mass., April 23 /PRNewswire/ -- TSI Corporation (NASDAQ: TSIN) announced today that it has completed the previously announced acquisition of the International Bio Research (IBR) subsidiary from PharmaKinetics Laboratories, Inc. IBR, located in Walsrode, Germany, is a leading provider of preclinical and toxicology testing services in Europe. TSI paid PharmaKinetics $1.95 million in cash and 158,528 shares of TSI Common Stock. PharmaKinetics is a drug development company providing services to pharmaceutical and biotechnology firms seeking new drug approvals in the United States and Europe.
 "The acquisition of IBR significantly enhances TSI's ability to serve its international clients," said James P. Sherblom, chairman and chief executive officer of TSI. "We look forward to IBR further solidifying TSI's position in services for biotechnology-based products and to its expected positive contribution to our operating results."
 TSI is a life sciences company offering in vitro, and in vivo preclinical and toxicology testing services, human clinical testing services, and diagnostic intermediate products. TSI is also developing advanced toxicology tests and disease models based on genetic engineering and transgenic techniques to improve the efficiency of the pharmaceutical/chemical development process.
 -0- 4/23/92
 /CONTACT: Munro Pitt, senior vice president of TSI Corporation, 508-755-0550; or Robert Gottlieb vice president of Feinstein Partners Inc., 617-577-8110, for TSI Corporation/
 (TSIN) CO: TSI Corporation ST: Massachusetts IN: MTC SU: TNM


DD -- NE003 -- 1646 04/23/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 23, 1992
Words:239
Previous Article:IN-STORE ADVERTISING REPORTS FIRST QUARTER RESULTS
Next Article:LEPERCQ FUNDS TERMINATE AGREEMENT WITH REALTY REFUND


Related Articles
TSI ANNOUNCES Q2 OUTLOOK AND MANAGEMENT APPOINTMENTS
TSI CORPORATION ANNOUNCES PUBLIC OFFERING OF 2.3 MILLION SHARES OF COMMON STOCK AT $12.50 PER SHARE
TSI ANNOUNCES CONVERTIBILITY OF PREFERRED STOCK
TSI CORPORATION ANNOUNCES PROPOSED ACQUISITION OF GERMAN PRECLINICAL TESTING FACILITY
TSI COMPLETES ACQUISITION OF HSRI
TSI CORPORATION TO ACQUIRE CLINICAL RESEARCH GROUP
TSI CORP. ANNOUNCES RESTRUCTURING AND FORECASTS YEAR-END RESULTS
TSI CORPORATION ANNOUNCES MANAGEMENT APPOINTMENTS
TSI CORPORATION TO WRITE DOWN INVESTMENT IN GERMAN SUBSIDIARY
TSI CORPORATION ANNOUNCES YEAR END 1993 RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters